Oncolytics Biotech Appoints Andrew Aromando Chief Business Officer

Oncolytics Biotech Inc. has appointed Andrew Aromando as Chief Business Officer to lead global business development and enhance the value of clinical data for pelareorep, an immunotherapeutic agent targeting multiple cancers including pancreatic, breast, and anal cancers. Aromando brings over 30 years of life sciences experience, notably playing a key role in the $2 billion acquisition of Ambrx Biopharma by Johnson & Johnson. His responsibilities include developing corporate, clinical, and regulatory strategies to accelerate pelareorep's path towards regulatory approval and commercialization. The company views Aromando's appointment as a strategic move to maximize pelareorep's value on an accelerated timeline, leveraging clinical evidence from over 1,100 patients. Aromando's compensation includes significant equity incentives such as stock options and restricted stock units tied to acquisition or licensing milestones. Despite ongoing financial challenges and speculative stock valuation, Oncolytics aims to capitalize on clinical advancements and Aromando's expertise to strengthen its market position.